Mark Levis

35PUBLICATIONS
145CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedMedical virologyMolecular targetsQuantum optics and quantum optomechanicsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jul 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

|Jun 04, 2026
ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|May 20, 2026
A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Feb 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

Pageof 6

Frequent Collaborators

12 joint publications

Alexander Perl

9 joint publications

Yi-Bin Chen

7 joint publications

Mehdi Hamadani

7 joint publications

Pau Montesinos